S.Korea's Daewoong Pharma gets approval for Phase 1 trials of COVID-19 anti-parasite drug

Daewoong Pharma

12/10/2020 08:05

By Sangmi Cha
    SEOUL, Oct 12 (Reuters) - South Korean drugmaker Daewoong
Pharmaceutical Co Ltd  069620.KS  said on Monday that it had
received regulatory approval for Phase 1 clinical trials of its
anti-parasitic niclosamide drug to treat COVID-19 patients.
    The approval comes after the company in August received
Indian regulatory approval to test the drug in Phase 1 trials.
 urn:newsml:reuters.com:*:nL4N2FD0WO
    The company confirmed the safety of the drug in its latest
study in partnership with New Delhi-based Mankind Pharma Ltd,
Daewoong said in a statement.  urn:newsml:reuters.com:*:nP8N2B802D
    In September, Daewoong separately launched another overseas
human trial of the drug in the Philippians.
    Daewoong plans to seek conditional approval for its
anti-viral drug, DWRX2003, for emergency use after securing the
results from a second-stage clinical study, the company said.
    Daewoong had said its anti-viral drug had completely
eliminated the novel coronavirus from animals' lungs during
pre-clinical testing.  urn:newsml:reuters.com:*:nL4N2DL1N5
    

 (Reporting by Sangmi Cha; Editing by Stephen Coates)
 ((Sangmi.Cha@thomsonreuters.com; +82 2 3704 5646; Reuters
Messaging: sangmi.cha.thomsonreuters.com@reuters.net))